Boryung Pharm (003850) - Net Assets
Based on the latest financial reports, Boryung Pharm (003850) has net assets worth ₩818.35 Billion KRW (≈ $554.58 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩1.36 Trillion ≈ $918.96 Million USD) and total liabilities (₩537.67 Billion ≈ $364.37 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 003850 asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩818.35 Billion |
| % of Total Assets | 60.35% |
| Annual Growth Rate | 13.09% |
| 5-Year Change | 130.54% |
| 10-Year Change | 438.09% |
| Growth Volatility | 14.26 |
Boryung Pharm - Net Assets Trend (2009–2024)
This chart illustrates how Boryung Pharm's net assets have evolved over time, based on quarterly financial data. Also explore 003850 total asset value for the complete picture of this company's asset base.
Annual Net Assets for Boryung Pharm (2009–2024)
The table below shows the annual net assets of Boryung Pharm from 2009 to 2024. For live valuation and market cap data, see 003850 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩784.50 Billion ≈ $531.65 Million |
+42.83% |
| 2023-12-31 | ₩549.25 Billion ≈ $372.22 Million |
+6.36% |
| 2022-12-31 | ₩516.42 Billion ≈ $349.97 Million |
+8.88% |
| 2021-12-31 | ₩474.31 Billion ≈ $321.44 Million |
+39.39% |
| 2020-12-31 | ₩340.29 Billion ≈ $230.61 Million |
+20.26% |
| 2019-12-31 | ₩282.95 Billion ≈ $191.75 Million |
+10.48% |
| 2018-12-31 | ₩256.10 Billion ≈ $173.56 Million |
+2.58% |
| 2017-12-31 | ₩249.65 Billion ≈ $169.19 Million |
+27.80% |
| 2016-12-31 | ₩195.35 Billion ≈ $132.39 Million |
+33.99% |
| 2012-12-31 | ₩145.79 Billion ≈ $98.80 Million |
+5.67% |
| 2011-12-31 | ₩137.97 Billion ≈ $93.50 Million |
+1.14% |
| 2010-12-31 | ₩136.41 Billion ≈ $92.44 Million |
+9.99% |
| 2009-12-31 | ₩124.01 Billion ≈ $84.04 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Boryung Pharm's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 551.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩466.64 Billion | 59.48% |
| Other Components | ₩317.86 Billion | 40.52% |
| Total Equity | ₩784.50 Billion | 100.00% |
Boryung Pharm Competitors by Market Cap
The table below lists competitors of Boryung Pharm ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hovnanian Enterprises Inc
NYSE:HOV
|
$569.25 Million |
|
VersaBank
TO:VBNK
|
$569.52 Million |
|
Worldline SA
PA:WLN
|
$569.63 Million |
|
Turvo International Co Ltd
TW:2233
|
$569.82 Million |
|
Ningbo Lehui International Engineering Equipment Co Ltd Class A
SHG:603076
|
$568.73 Million |
|
Shenzhen Silver Basis Technology Co Ltd
SHE:002786
|
$568.59 Million |
|
GuangDong GenSho Logistics Co
SHG:603813
|
$568.58 Million |
|
Zhejiang Extek Technology Co. Ltd. A
SHE:301399
|
$568.56 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Boryung Pharm's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 548,749,644,990 to 784,503,260,930, a change of 235,753,615,940 (43.0%).
- Net income of 69,633,253,500 contributed positively to equity growth.
- Dividend payments of 6,766,571,000 reduced retained earnings.
- New share issuances of 174,999,991,690 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩69.63 Billion | +8.88% |
| Dividends Paid | ₩6.77 Billion | -0.86% |
| Share Issuances | ₩175.00 Billion | +22.31% |
| Other Changes | ₩-2.11 Billion | -0.27% |
| Total Change | ₩- | 42.96% |
Book Value vs Market Value Analysis
This analysis compares Boryung Pharm's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.06x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 1.90x to 1.06x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ₩5237.60 | ₩9940.00 | x |
| 2018-12-31 | ₩5431.54 | ₩9940.00 | x |
| 2019-12-31 | ₩6001.01 | ₩9940.00 | x |
| 2020-12-31 | ₩7388.39 | ₩9940.00 | x |
| 2021-12-31 | ₩7167.85 | ₩9940.00 | x |
| 2022-12-31 | ₩7830.49 | ₩9940.00 | x |
| 2023-12-31 | ₩8331.34 | ₩9940.00 | x |
| 2024-12-31 | ₩9343.45 | ₩9940.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Boryung Pharm utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.88%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.85%
- • Asset Turnover: 0.87x
- • Equity Multiplier: 1.48x
- Recent ROE (8.88%) is above the historical average (8.60%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 4.18% | 1.93% | 1.52x | 1.43x | ₩-7.22 Billion |
| 2010 | 10.52% | 4.77% | 1.22x | 1.80x | ₩708.18 Million |
| 2011 | 4.48% | 2.01% | 1.17x | 1.90x | ₩-7.62 Billion |
| 2012 | 6.45% | 3.01% | 1.14x | 1.87x | ₩-5.18 Billion |
| 2016 | 2.87% | 1.37% | 1.03x | 2.04x | ₩-13.92 Billion |
| 2017 | 22.71% | 13.41% | 1.05x | 1.61x | ₩31.73 Billion |
| 2018 | 7.93% | 4.41% | 1.02x | 1.76x | ₩-5.30 Billion |
| 2019 | 11.39% | 6.15% | 1.03x | 1.79x | ₩3.93 Billion |
| 2020 | 7.90% | 4.78% | 0.87x | 1.91x | ₩-7.13 Billion |
| 2021 | 9.08% | 6.86% | 0.76x | 1.75x | ₩-4.34 Billion |
| 2022 | 8.12% | 5.51% | 0.85x | 1.73x | ₩-9.70 Billion |
| 2023 | 7.33% | 4.68% | 0.94x | 1.67x | ₩-14.67 Billion |
| 2024 | 8.88% | 6.85% | 0.87x | 1.48x | ₩-8.82 Billion |
Industry Comparison
This section compares Boryung Pharm's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $539,974,734,813
- Average return on equity (ROE) among peers: 2.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Boryung Pharm (003850) | ₩818.35 Billion | 4.18% | 0.66x | $569.08 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.73 Billion | 2.15% | 0.36x | $113.83 Million |
| Yuhan Corp. (000100) | $1.85 Trillion | 10.44% | 0.30x | $4.57 Billion |
| Yuhan Corp Preferred (000105) | $1.36 Trillion | 9.24% | 0.38x | $59.61 Million |
| Yuyu Pharma (000220) | $73.73 Billion | -0.34% | 0.41x | $46.55 Million |
| Yuyu Pharma Inc (000225) | $73.73 Billion | -0.34% | 0.41x | $17.67 Million |
| Yuyu Pharma Inc (000227) | $128.69 Billion | -1.72% | 0.50x | $42.93 Million |
| Ildong Holdings Co Ltd (000230) | $332.95 Billion | 3.56% | 0.86x | $76.14 Million |
| Samil Pharm (000520) | $176.12 Billion | -3.20% | 1.24x | $127.90 Million |
| Donga Socio Holdings (000640) | $914.25 Billion | 3.56% | 0.60x | $427.15 Million |
| Jw Pharmac (001060) | $260.11 Billion | 3.10% | 1.28x | $476.78 Million |
About Boryung Pharm
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmaceutical Co., Ltd. and changed its name to Boryung Corporation in March 2022. Boryung Corporation was founded in 1957 and is headquartered in Seoul, So… Read more